Funding Opportunities Announced

The FY19 Defense Appropriation provides $15 million (M) to the Department of Defense Peer Reviewed Alzheimer’s Research Program (PRARP) to support research which addresses the long-term consequences of traumatic brain injury (TBI) as they pertain to Alzheimer’s disease (AD) and related dementias (ADRD). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.

Convergence Science Research Award – Letter of Intent due June 26, 2019

Level I: The Principal Investigator (PI) must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).

Level II: The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Intent: Support innovative or novel efforts to generate research resources, tools, or research efforts for researchers and/or practitioners in health sciences.

Applications must address one or more of the following FY19 PRARP Overarching Challenges:

  • Paucity of Research Resources
  • Paucity of Clinical Studies
  • Diagnostics and Prognostics
  • Epidemiology

Applications should address at least one of the following FY19 PRARP Focus Areas:

  • Mechanisms of Pathogenesis
  • Biomarkers
  • Epidemiology
  • Novel Target Identification
  • Bioinformatics

Research considering pharmacologic interventions is specifically discouraged under this mechanism.

Preliminary data, while not required, are encouraged.

Level I:

  • Maximum funding of $225,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.
  • Indirect costs may be proposed in accordance with the institution's rate agreement.

Level II:

  • Maximum funding of $500,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.
  • Indirect costs may be proposed in accordance with the institution's rate agreement.

Innovation in Care and Support award – Letter of Intent due June 26, 2019

Level 1: The PI must be an independent, early-career investigator within 3 years of his/her first independent faculty position (or equivalent).

Level II: The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent)

Intent: To support innovative research that improves the quality of life and care for individuals living with the common symptoms of TBI and/or Ad/ADRD and/or their families and care providers.

Applications must address one or more of the following FY19 PRARP Overarching Challenges:

  • Paucity of Clinical Studies
  • Diagnostics and Prognostics
  • Epidemiology
  • Quality of Life
  • Family and Care Support

Applications should address at least one of the following FY19 PRARP Focus Areas:

  • Biomarkers
  • Quality of Life
  • Family and Caregiver Support
  • Epidemiology
  • Nonpharmacological Interventions and Devices
  • Bioinformatics
  • Research considering pharmacologic interventions is specifically discouraged under this mechanism.
  • Preliminary data, while not required, are encouraged.

Level I:

  • Maximum funding of $225,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.
  • Indirect costs may be proposed in accordance with the institution's rate agreement.

Level II:

  • Maximum funding of $500,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.
  • Indirect costs may be proposed in accordance with the institution's rate agreement

Research Partnership Award – Letter of Intent due June 26, 2019

The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Intent: To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts.

Applications must include clearly stated plans for interactions between the partners.

Applications must address one or more of the following FY19 PRARP Overarching Challenges:

  • Paucity of Research Resources
  • Paucity of Clinical Studies
  • Diagnostics and Prognostics
  • Epidemiology
  • Quality of Life
  • Family and Care Support

Applications should address at least one of the following FY19 PRARP Focus Areas:

  • Mechanisms of Pathogenesis
  • Biomarkers
  • Quality of Life
  • Family and Caregiver Support
  • Epidemiology
  • Novel Target Identification
  • Nonpharmacological Interventions and Devices
  • Bioinformatics
  • Research considering pharmacologic interventions is specifically discouraged under this mechanism.
  • Preliminary data are required.
  • Funding limit is $1.3M in total costs.
  • Maximum period of performance is 3 years.
  • Indirect costs may be proposed in accordance with the institution’s rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov.